The adverse prognostic impact of advanced age in multiple myeloma

References

• Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S, Mehta J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533–539.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, Moller H. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299–304.
   Google Scholar
• Kyle RAaBJ. Multiple myeloma and related disorders. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical oncology. 2nd ed. New York: Churchill Livingstone; 2000. pp 2597–2619.
   Google Scholar
• Penson RT, Daniels KJ, Lynch TJ, Jr. Too old to care? Oncologist 2004;9(3):343–52.
   PubMed Web of Science ®Google Scholar
• Zagonel V, Monfardini S, Tirelli U, Carbone A, Pinto A. Management of hematologic malignancies in the elderly: 15-year experience at the Avian° Cancer Center, Italy. Crit Rev Oncol Hematol 2001;39: 289–305.
   Google Scholar
• Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Chin Oncol 1994;12: 1577–1583.
   Google Scholar
• Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001;39:219–226.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Chin Proc 2003;78:21–33.
   PubMed Web of Science ®Google Scholar
• Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P. Multiple myeloma in elderly patients: Presenting features and outcome. Eur J Haematol 2001;66:11–17.
   PubMed Web of Science ®Google Scholar
• Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, Nielsen JL, Oden A, Seidel C, Waage A, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999;106:1005–1012.
   PubMed Web of Science ®Google Scholar
• Corrado C, Santarelli MT, Pavlovsky S, Pizzolato M. Prognostic factors in multiple myeloma: Definition of risk groups in 410 previously untreated patients: a Grupo Argentin° de Tratamiento de la Leucemia Aguda study. J Chin Oncol 19897:1839-1844.
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora 0, Brugnatelli S, Tinelli C, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Bergonzi C, Giordano M, et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: Updated results of the M1\487 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998;77: 485–491.
   Google Scholar
• Blade J, Munoz M, Fontanillas M, San Miguel J, Alcala A, Maldonado J, Besses C, Moro MJ, Garcia-Conde J, Rozman C, et al. Treatment of multiple myeloma in elderly people: Long-term results in 178 patients. Age Ageing 1996;25: 357–361.
   Google Scholar
• Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multi-ple myeloma. N Engl J Med 2003;348:1875–1883.
   Google Scholar
• Fermand JP, Ravaud P, Katsahian S, et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age [abstract]. Blood 1999;94 (Suppl 1):396a.
   Google Scholar
• Blade J, Sureda, A, Ribera JM, et al. High-dose therapy/ autotransplantation/intensification versus continued conven-tional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months [abstract]. Blood 2003;102:42a.
   Google Scholar
• Palumbo A, Bringhen, S, Petrucci, MT, et al. A prospective randomized trial of intermediate dose melphalan (100 mg/ m2) cs oral melphalan/prednisolone [abstract]. Blood 2003;102:984a.
   Web of Science ®Google Scholar
• Barlogie B, Kyle R, Anderson K, et al. Comparable survival in multiple myeloma with high dose therapy employing Mel 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon maintenance: Results of Intergroup trial S9321 [abstract]. Blood 2003;102:42a.
   Web of Science ®Google Scholar
• Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Chin Oncol 2000;18:1709–1717.
   Google Scholar
• Dale DC. Poor prognosis in elderly patients with cancer: The role of bias and undertreatment. J Support Oncol 2003;1(4 Suppl 2): 11–17.
   Google Scholar
• Peake MD, Thompson S, Lowe D, Pearson MG. Ageism in the management of lung cancer. Age Ageing 2003;32 (2):171–177.
   PubMed Web of Science ®Google Scholar
• Mahoney T, Kuo YH, Topilow A, Davis JM. Stage III colon cancers: Why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 2000;135:182–185.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Putt M, Zhang Y, Glick JH, Norman S. Older age predicts a decline in adjuvant chemotherapy recommen-dations for patients with breast carcinoma: Evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 2003;97:2150–2159.
   Google Scholar
• Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997;20:435–443.
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in cancer treatment: A potential role in the elderly? Drugs Aging 2002;19:85–100.
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM and others. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Chin Oncol 2000;18:708–715.
   Google Scholar
• Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001;1:278–284.
   Google Scholar
• Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG, Wals J, Schouten HC. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: A retrospective population-based study. Ann Hematol 2001;80:155–159.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Triolo S, Argentin° C, Bringhen S, Dominietto A, Rus C, Omede P, Tarella C, Pileri A, Boccadoro M. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94: 1248–1253.
   Google Scholar
• Rao AV, Seo PH, Cohen HJ. Geriatric assessment and comorbidity. Semin Oncol 2004;31:149–159.
   Google Scholar
• Balducci L. New paradigms for treating elderly patients with cancer: The comprehensive geriatric assessment and guide-lines for supportive care. J Support Oncol 2003;1(4 Suppl 2):30–37.
   Google Scholar
• Yellen SB, Cella DF. Someone to live for: Social well-being, parenthood status, and decision-making in oncology. J Chin Oncol 1995;13:1255–1564.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994;86:1766–1770.
   PubMed Web of Science ®Google Scholar
• Rose JH, O'Toole EE, Dawson NV, Lawrence R, Gurley D, Thomas C, Hamel MB, Cohen HJ. Perspectives, prefer-ences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Chin Oncol 2004;22(24):4907–4917.
   PubMed Web of Science ®Google Scholar
• Pinquart M, Duberstein PR. Information needs and deci-sion-making processes in older cancer patients. Grit Rev Oncol Hematol 2004;51:69–80.
   PubMed Web of Science ®Google Scholar
• Kutner JS, Vu KO, Prindiville SA, Byers TE. Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract 2000;8:114–119.
   PubMedGoogle Scholar
• Mileshkin L, Biagi jj, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K and others. Multicenter phase 2 trial of thalidomide in relapsed/ refractory multiple myeloma: Adverse prognostic impact of advanced age. Blood 2003;102: 69–77.
   Google Scholar
• Corso A, Klersy C, Lazzarino M, Bernasconi C. Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol 1998;76:67–72.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72: 219–223.
   Google Scholar
• Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst 1982;68:729–733.
   Google Scholar
• Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, et al. Simple prognostic model for patients with multiple myeloma: A single-center study in Japan. Ann Hematol 2002;81:33–36.
   PubMed Web of Science ®Google Scholar
• Suguro M, Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol 2000;65:132–135.
   Google Scholar
• Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V, Saso R, Horton C, Bhagwati N, Singhal S and others. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999;107: 656–666.
   Google Scholar
• Matzner Y, Benbassat J, Polliack A. Prognostic factors in multiple myeloma: A retrospective study using conventional statistical methods and a computer program. Acta Haematol 1978;60:257–268.
   Google Scholar
• Hannisdal E, Kildahl-Andersen 0, Grottum KA, Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol 1990;45:198–202.
   Google Scholar
• Pennec Y, Mottier D, Youinou P, Asselain B, Chavance M, Le Goff P, Le Prise PY, Miossec P, Le Menn G. Critical study of staging in multiple myeloma. Scand J Haematol 1983;30:183–190.
   Google Scholar
• Froom P, Quitt M, Aghai E. Multiple myeloma in the geriatric patient. Cancer 1990;66:965–967.
   Google Scholar
• Greipp PR, San Miguel JF, Fonseca R, Avet-Loiseau H, Jacobsen JI,, Rasmussen E, Crowley JJ, Dune BGM. Development of an International Prognostic Index (IPI) for myeloma: Report of the International Myeloma Working Group. Salamanca, Spain. Hematol J 2003;4 (Suppl 1): abstr S45.
   Google Scholar
• English D, Giles G, Karavarsamis N, Thursfield V. Cancer survival in Victoria: Relative survival for selected cancers diagnosed from 1982 to 1997 with follow-up to 1999:Victor-ian Cancer Registry, Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne; 2003.
   Google Scholar
• Clavio M, Casciaro S, Gatti AM, Spriano M, Bonanni F, Poggi A, Vallebella E, Pietrasanta D, Prencipe E, Goretti R and others. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996;81: 238–244.
   Google Scholar
• Fratino L, Serraino D, Zagonel V. The impact of cancer on the physical function of the elderly and their utilization of health care. G.I.O. Ger (Gruppo Italiano Oncologia Geria-trica). Cancer 1998;83:589–591.
   Google Scholar
• Cohen HJ, Bartolucci A. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. Am J Med 1985;79:316–324.
   Google Scholar
• Cohen HJ, Silberman HR, Forman W, Bartolucci A, Liu C. Effects of age on responses to treatment and survival of patients with multiple myeloma. J Am Geriatr Soc 1983;31:272–277.
   Google Scholar
• Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc 1994;42:653–664.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Kellermeyer RW, Aikawa M, Herzig RH. Multiple myeloma in young men. Clinical course and electron microscopic studies of bone marrow plasma cells. Cancer 1980;46:1397–1400.
   Google Scholar
• Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93: 345–351.
   Google Scholar
• Clough V, Delamore IW, Whittaker JA. Multiple myeloma in a young woman. Ann Intern Med 1977;86:117–118.
   PubMed Web of Science ®Google Scholar
• Khunger JM, Sharma M, Talib VH. Multiple myeloma presenting as primary non-secretory plasma cell leukemia. Indian J Pathol Microbiol 2003;46:104–105.
   Google Scholar
• Chen CC, Gau JP, Ho CH, Lin JS, Chiou HJ, Lirng JF. Aggressive multiple myeloma with brain involvement in a young patient. J Chin Med Assoc 2003;66:177–180.
   PubMedGoogle Scholar
• Nilsson T, Hoglund M, L,enhoff S, Rylander L, Turesson I, Westin J, Mitelman F, Johansson B. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals fre-quently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003;120: 960–969.
   Google Scholar
• Westin EH, Longo DL. Lymphoma and myeloma in older patients. Semin Oncol 2004;31:198–205.
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Collaborative Group. Combination che-motherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. 'J Chin Oncol 1998;16: 3832–3842.
   Google Scholar
• Peest D, Coldewey R, Deicher H, Sailer M, Vykoupil C, Leo R, Georgii A, Karow J, Hoeppner E, Diehl V, et al. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: Improved definition of risk groups. Eur J Cancer 1993;29A:978–983.
   PubMed Web of Science ®Google Scholar
• Palva IP, Ahrenberg P, Ala-Harja K, Almqvist A, Hanninen A, Ilvonen M, Isomaa B, Jouppila J, Jarvenpaa E, Kilpi H, et al. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Eur J Haematol 1989;43:328–331.
   PubMed Web of Science ®Google Scholar
• Gulbrandsen N, Hjermstad MJ, Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72:172–180.
   Google Scholar
• Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11:1427–1436.
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113: 1020–1034.
   Google Scholar
• Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163–3168.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, Prentice G, Cavo M, Samson D, de Laurenzi A and others. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT Registry Study. European Group for Bone Marrow Trans-plantation. Leuk Lymphoma 1994;15(3-4):265–272.
   Google Scholar
• Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG and others. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hemato-logic malignancies. J Chin Oncol 1997;15:18–25.
   Google Scholar
• Harousseau JL, Shaughnessy J, Jr., Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004:237–256.
   Google Scholar
• Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplanta-tion in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6 (2A): 204–210.
   Google Scholar
• Mileshkin L, Prince, H.M., Seymour, J.F. Increased, but manageable, cardiovascular toxicity during high-dose che-motherapy and autologous peripheral blood stem cell transplantation for patients aged / 60 years. Salamanca, Spain. Hematol J 2003;4 (Suppl 1): abstr 275. p S209.
   Google Scholar
• Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timo-feeva I, Bertuzzi A, Compasso S, Nozza A, Siracusano L, Santoro A. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lympho-ma: survey from a single institution. Am J Hematol 2003;73:267–272.
   Google Scholar
• Villela L, Sureda A, Canals C, Sanz MA, Jr., Martino R, Valcarcel D, Altes A, Briones J, Gomez M, Brunet S. Low transplant related mortality in older patients with hematolo-gic malignancies undergoing autologous stem cell transplantation. Haematologica 2003;88:300–305.
   Google Scholar
• Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK, Elfenbein GJ, Freytes CO, Gale RP, Gertz MA, et al. Autologous stem cell transplantation in multiple myeloma patients 60 vs / 60 years of age. Bone Marrow Transplant 2003;32:1135–1143.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51–54.
   PubMed Web of Science ®Google Scholar
• Bathos A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600–607.
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Saavedra S, Sanz GF, Martin G, Moscardo F, Martinez J, Jarque I, Jimenez C, Sanz MA. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:21–25.
   PubMed Web of Science ®Google Scholar
• Lahuerta jj, Martinez-Lopez J, Grande C, Blade J, de la Serna J, Alegre A, Garcia-Larana J, Caballero D, Sureda A, de la Rubia J, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A compara-tive study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000;109:138–147.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Arial M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731–735.
   PubMed Web of Science ®Google Scholar
• Fietz T, Rieger K, Dimeo F, Blau IW, Thiel E, Knauf WU. Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly? J Chin Apheresis 2004;19:202–207.
   PubMed Web of Science ®Google Scholar
• Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34 + cells in elderly patients ( / 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120: 413–423.
   Google Scholar
• Prince HM, Imrie K, Sutherland DR, Keating A, Meharc-hand J, Crump RM, Girouard C, Trip K, Stewart AK. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collec-tions. Br J Haematol 1996;93:142–145.
   Google Scholar
• Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdal-lah R, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–2502.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447–3454.
   Google Scholar
• Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Togel F, Wittkowsky G, Kuse R, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755–760.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Anderson KC. Multiple myeloma: how far have we come? Mayo Chin Proc 2003;78:15–17.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood 2004;103:20–32.
   PubMed Web of Science ®Google Scholar
• Richardson P, Anderson K. Imrnunomodulatory analogs of thalidomide: An emerging new therapy in myeloma. J Chin Oncol 2004;22:3212–3214.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R and others. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609–2617.
   Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Chin Oncol 2003;21:4444–4454.
   Google Scholar
• Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA and others. Combination therapy with thalidomide plus dexa-methasone for newly diagnosed myeloma. J Chin Oncol 2002;20:4319–4323.
   Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Chin Oncol 2003;21:16–19.
   Google Scholar
• Yakoub-Agha I, Arial M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002;3: 185–192.
   Google Scholar
• Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Chin Cancer Res 2002;8:3377–3382.
   Google Scholar
• Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, Lopez R, Grande-Garcia C, Alegre A, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (Tha-CyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856–863.
   PubMed Web of Science ®Google Scholar
• Dune BG. Low-dose thalidomide in myeloma: Efficacy and biologic significance. Semin Oncol 2002;29(6 Suppl 17):34–38.
   Google Scholar
• Offidani M, Corvatta L, Marconi M, Olivieri A, Catarini M, Mele A, Brunori M, Candela M, Malerba L, Capelli D, et al. Thalidomide plus oral melphalan compared with thalido-mide alone for advanced multiple myeloma. Hematol J 2004;5:312–317.
   PubMedGoogle Scholar
• Palumbo A, Bertola, A., Musto P. et al. A prospective randomized trial of oral melphalan, prednisolone, thalido-mide (MPT) vs oral melphalan, prednisolone (MP): An interim analysis [abstract]. Blood 2004;104:207a.
   Google Scholar
• Hussein MA. Thalidomide, age, and future use in multiple myeloma. Blood 2003;102:2–3.
   Web of Science ®Google Scholar